Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Clinical Study Exploring the Safety, Tolerability, and Preliminary Efficacy of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Interstitial Lung Disease (ILD)

NCT06534528 is registered in ClinicalTrials.gov with Shanghai Life Science & Technology as lead sponsor.

NCT NCT06534528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06534528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Clinical Study Exploring the Safety, Tolerability, and Preliminary Efficacy of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Interstitial Lung Disease (ILD)
Lead sponsor
Shanghai Life Science & Technology
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
October 1, 2027
Enrollment
24 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

interstitial lung disease